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Editorial

The Meta-Analysis in Evidence-Based Medicine:
High-Quality Research When Properly Performed
The origins of evidence-based medicine (EBM) trace back
to the mid-19th century1 and the gradual evolution from personal journals to textbooks and eventually the advent of the
peer-reviewed journal. Evidence-based medicine originally
was defined by David Sackett as the “conscientious, explicit,
and judicious use of current best evidence in making decisions
about the care of individual patients.”2 Researchers from
McMasters University began to introduce the term into the
medical litrerature more systematically in the mid 1990s. Further analyzed, its aims include integrating individual clinical
expertise (proficiency and judgment that individual clinicians
acquire through clinical experience and practice) with the best
available external clinical evidence from systematic research
and patient’s preferences to guide care.1 Over the years, EBM
has become the core guiding principle for those studying
patient outcomes.3 The lower end of this paradigm includes
unsystematic observations and narrative reviews, while at the
opposite end lie methodologically sound, homogeneous, randomized clinical trials (RCTs). Systematic reviews and metaanalyses of homogeneous RCTS have been given the highest
level of evidence. In its strictest definition, a metaanalysis
(“analysis of analyses”) is a formal, epidemiologic, quantitative statistical technique that analyzes the results of different
studies on the same topic and integrates the evidence into a
single conclusion.4,5 By combining individual studies, and
thus using more data from a larger sample size, the precision
and accuracy of the estimates in the individual studies can be
improved upon—essentially improving the strength of the evidence. The key point is that a sound metaanalysis eliminates
all bias by employing a strict methodologic/statistical
approach and in the process provides evidence of the highest
quality—with minimal heterogeneity. Additionally, if the individual studies were underpowered, combining them in a metaanalysis can increase the overall statistical power to detect an
effect. When properly performed, meta-analyses can improve
precision of effect estimates, generate clinically meaningful
answers to questions that individual studies might not be able
to accomplish, and even settle controversies from studies that
may be conflicted.4
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The Cochrane Collaboration, an international organization,
was developed to aid researchers generate systematic reviews
of the highest quality and has become a key point of reference
for researchers interested in producing and disseminating
accurate data comparing treatment effectiveness.6 However, in
the present day, the metaanalysis arguably has been abused,
contributing to misleading conclusions rather than proper evidence-based information. The increasing popularity of metaanalyses can be traced to industrialized nations worldwide,
most notably in China. According to PubMed data, 1.3% of
publications by Chinese researchers in 2011 were metaanalyses, compared to 0.4% for authors from the rest of the world.7
This popularity is, in part, due to the pressure to publish on
individual researchers for academic achievement and visibility7 instead of a meaningful contribution to the evidence, and
has contributed to this pandemic with flawed and erroneous
concepts in design, conduct, statistical analysis, and reporting
that have plagued virtually every specialty of medicine.
Redundant, Misleading and Conflicted Data
The incredible popularity of the metaanalysis has led to significant redundancy in data reporting, particularly in outcomes.
The extent of redundancy, particularly in meta-analyses of randomized trials, has reached epidemic proportions.8 Examples
of this can be seen in multiple fields, with original meta-analyses showing statistically significant and clinical benefit, followed by subsequent similar meta-analyses, some with
identical results and very few actually citing systematically
among their references the prior metaanalyses on the same
topic. This has led to the current perception of the metaanalysis
as inferior research and a possibly diminished role in evidencebased clinical research. More so in cardiovascular medicine,
journals are prone to have high levels of hidden biases in
accepting manuscripts (articles from prominent researchers or
major research institutes) despite significant redundancy of the
topic in question in the medical literature. The sine qua non of
the metaanalysis is the proper identification of existing literature and the systematic search of existing evidence. For this, a
protocol that lists all potential sources and strategies should be
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established first. The authors believe that to help solidify the
results and encourage transparency in the metaanalytic process, all metaanalyses should be registered in dedicated international databases of prospectively registered systematic
reviews, such as PROSPERO.9 Registration allows those who
are commissioning or planning studies to identify whether
there are other metaanalyses already underway that are
addressing their topic of interest. This helps provide transparency and avoid unintended and economically wasteful duplication of effort. It also serves as a safeguard against reporting
biases by revealing differences between the outcomes reported
and those planned in the registered protocol. This will improve
the quality and credibility of metaanalyses endpoints and
increase confidence behind policy or practice, informed by the
findings of a systematic review drawing on the best-quality
evidence.
The Search Process Is Critical
A significant factor instrumental in the final results of a
metaanalysis lies in the search process; the most commonly
used electronic databases may include MEDLINE and
EMBASE.10,11 This can create an inherent bias from inception
to find studies published only in English and excluding nonindexed studies in peer-reviewed journals, leading to only a sample of available evidence worldwide.12 This is referred to as
“publication bias”, and it is defined properly as the occurrence
of studies showing positive effects being published and cited
more frequently versus studies that show no significant
results.12,13 This could lead to published data overestimating
the actual degree of effect of the therapy or management studied.12,13 Trends show that larger studies with publication bias
tend to get published regardless of their results. Studies that
have small positive effects or reject the null hypothesis tend
not to materialize in popular databases, whether it be due to
publication delay, publications in languages other than
English, publications in nonindexed journals, or studies not
being published altogether. Therefore, reviewers may not be
able to identify them. To minimize bias associated with narrow
collection of sources and usage of only the most popular databases, one needs to broaden the scope of databases used. This
includes electronic sources such as Cochrane Central,14 the
Federal Drug Administration, and internet websites such as
Google Scholar. Examples of search strategies can be found in
the Cochrane Collaboration’s Reviewers’ handbook.15 The
basic search strategy is built based on the research question
formulation (ie, PICO or PICOS-Patient/ Problem, Intervention, Comparison and Outcome). Search strategies are constructed to include free-text terms (eg, in the title and abstract)
and any appropriate subject indexing (eg, Medical Subject
Headings) expected to retrieve eligible studies, with the help
of an expert in the topic or an information specialist.
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heterogeneous. Heterogeneity in metaanalysis refers to the variation in study outcomes between studies. There are three types
of heterogeneity: clinical, statistical, and design-related. There
is debate among researchers in how one would define heterogeneity—whether just based on a statistical variable using a
quantitative test such as the Cochran’s Q value or the I2 value.4
It has become a common practice to establish an I2 of 50%
(defining the study as heterogeneous) and to disregard the
qualitative background of a study due to this cause. Clinical
heterogeneity should be defined before quantitative analysis to
overcome differences between sample characteristics and
properly define the best method of analysis. Qualitative analysis of the heterogeneity due to the characteristics mentioned
would provide value over analysis from a statistical test and
could shed light over important determinants of treatment
effect and increase the scientific and clinical value of the metaanalysis.16 Exploration of these differences often may yield
new insights and hypotheses. Regarding statistical heterogeneity and mixing of studies, the authors’ approach to decrease
this value includes lowering this threshold to a more rigorous
accepted I2 of 25% or less to improve the inconsistency regarding selection of methods. The examination of all three types of
heterogeneity is a crucial methodologic issue in systematic
reviews and metaanalyses.
Modeling Effect Sizes
Although a complete discussion of all models available is
beyond the scope of this editorial, the authors briefly will discuss two statistical models for a metaanalysis, fixed-effect,
and random-effect models. Fixed-effect models assume that
the included studies have nonrandom variables and one true
effect size, and that variation is caused by sample errors or
chance (intrastudy errors).17 Random-effect models assume
the opposite, that the studies exhibit diversity and variability
attributed not only to random chance (intrastudy and interstudy
errors), with more than one effect size.18 The authors’ belief is
that specific selection of a model should be justified based on
types of studies, quantitative heterogeneity, and qualitative
heterogeneity, and not solely on statistical heterogeneity.
When there is discrepancy between models, both should be
used as a sensitivity analysis, allowing the reader to interpret
the data with more granularity. The flawed data from poorquality metaanalyses can lead very easily to significant shifts
in the delivery of healthcare from flawed guideline recommendations, which use metaanalytical data as the highest-quality
evidence. Also, many clinicians, researchers, and editors may
not be knowledgeable about how to differentiate between
high- and low-quality studies, and some biases may evade the
attention of even experienced methodologists and statistical
editors
Bias

Defining Heterogeneity
Another critical component of the metaanalysis is defining
heterogeneity and which cutoff value is defined as

To address publication bias, methodologists have proposed
several statistical and graphic strategies to determine whether
a metaanalysis is affected.12 Although none of these strategies
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is accepted widely, the most commonly used is the funnel
plot.19 However, a common problem with usage of the funnel
plot to identify evidence of asymmetry and publication bias is
that it is subjective and purely visual. It is not a formal statistical test. Presenting a funnel plot in a metaanalysis may be
highly misleading, particularly when then are ten or fewer
studies in the analysis.20 Studies using funnel-plot asymmetry
to assess publication bias pose several problems, including
subjectivity on whether a plot is asymmetric, the amount of
asymmetry required to have evidence of bias, likelihood of
asymmetry with publication bias, and whether asymmetric
plots can occur by chance. A formal statistical test of asymmetry, such as Egger’s test, generally should be preferred to funnel plots. Although Egger’s test lacks statistical power, it can
show appropriate type I error.21
Reporting
To maintain the quality and standard of reporting metaanalyses, especially with randomized controlled trials (RCTs),
there have been mandates over time to help classify important
practices. One such mandate is the Quality of Reporting of
Metaanalyses statement, which consists of a checklist and a
flow diagram.5 The checklist is organized into 21 headings and
subheadings that encourage the authors to provide information
on searches, selection, validity, assessment, data abstraction,
study characteristics, quantitative data synthesis, and trial
flow.5 The flow diagram provides information about the number of RCTs identified, included, and excluded and the reasons
for doing so.5 This statement was revised and improved upon
later with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses statement. This template updates
the format to consist of a 27-item checklist (inclusive of the
Quality of Reporting of Metaanalyses criteria) and four-phase
flow diagram, along with expanding its reach from metaanalyses to include other types of research that include RCTs.22
The metaanalysis will remain a powerful tool in the research
armamentarium, especially in cardiovascular medicine; there
is, however, a pressing need for greater attention to the basic
principles and crucial issues that the authors briefly have outlined. It will continue to provide high-level evidence for or
against a therapy in question, but, as always, the devil is in the
details.
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